Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500359 | 0.77 | — | — | |
| SCHEMBL500142 | 0.77 | — | — | |
| SCHEMBL10914495 | 0.74 | NAAA (0.30) | — | |
| SCHEMBL3633069 | 0.64 | GABRA1 (0.30) | PSMB5 | |
| SCHEMBL8942615 | 0.64 | — | — | |
| SCHEMBL790735 | 0.62 | — | — | |
| SCHEMBL2971407 | 0.62 | — | — | |
| SCHEMBL8877586 | 0.61 | HMGCR (0.34) | — | |
| SCHEMBL2605772 | 0.60 | CYP17A1 (0.36) | — | |
| SCHEMBL15539926 | 0.60 | HTT (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0093922-B1 | BENZOXAZIN-2-ONES, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1986-12-30 | — | — | EP | claimed |
| US-4323569-A | β-Lactam anti-bacterial, compositions containing them and a process for their preparation | BEECHAM GROUP LIMITED (GB) | 1982-04-06 | — | — | US | claimed |
| EP-0008514-B1 | BETA-LACTAM ANTI-BACTERIALS, COMPOSITIONS CONTAINING THEM AND A PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | claimed |
| EP-0008514-A1 | Beta-lactam anti-bacterials, compositions containing them and a process for their preparation | BEECHAM GROUP PLC (GB) | 1980-03-05 | — | — | EP | claimed |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3683209-B1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | AKEBIA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| EP-0093922-B1 | BENZOXAZIN-2-ONES, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| US-4518597-A | THROMBOSIS, ARTERIOSCLEROSIS, ANTITUMOR, ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
| EP-0093922-A2 | Benzoxazin-2-ones, their preparation and therapeutic agents containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-11-16 | — | — | EP | disclosed |
| US-4323569-A | β-Lactam anti-bacterial, compositions containing them and a process for their preparation | BEECHAM GROUP LIMITED (GB) | 1982-04-06 | — | — | US | disclosed |
| EP-0008514-B1 | BETA-LACTAM ANTI-BACTERIALS, COMPOSITIONS CONTAINING THEM AND A PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0008514-A1 | Beta-lactam anti-bacterials, compositions containing them and a process for their preparation | BEECHAM GROUP PLC (GB) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | PSMB5 2089/4885 |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | PSMB5 2089/4885 |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | HPD, APEH, P4HA1 | PSMB5 2089/4885 |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | PSMB5 2089/4885 |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | PSMB5 2089/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PSMB5 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.